JPH08503699A - 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 - Google Patents
全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体Info
- Publication number
- JPH08503699A JPH08503699A JP6510442A JP51044294A JPH08503699A JP H08503699 A JPH08503699 A JP H08503699A JP 6510442 A JP6510442 A JP 6510442A JP 51044294 A JP51044294 A JP 51044294A JP H08503699 A JPH08503699 A JP H08503699A
- Authority
- JP
- Japan
- Prior art keywords
- uridine
- endotoxin
- administering
- animal
- cytidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Abstract
Description
Claims (1)
- 【特許請求の範囲】 請求項1.治療的に有効量のピリミジンヌクレオチド前駆体を動物に投与するこ とよりなる、全身性炎症性応答症候群による組織損傷を治療または防止する方法 。 請求項2.治療的に有効量のピリミジンヌクレオチド前駆体を動物に投与するこ とよりなる、敗血症を治療または防止する方法。 請求項3.ピリミジンヌクレオチド前駆体は、ウリジン、シチジン、オロト酸、 あるいはウリジン、シチジン、またはオロト酸のアシル誘導体、あるいは薬剤と して許容されるその塩である、請求項2に記載の方法。 請求項4.ウリジンのアシル誘導体はトリアセチルウリジンである、請求項3に 記載の方法。 請求項5.動物はヒトである、請求項2に記載の方法。 請求項6.さらにウリジンホスホリラーゼの阻害剤を投与することよりなる、請 求項2に記載の方法。 請求項7.治療的に有効量のウリジンホスホリラーゼの阻害剤を動物に投与する ことよりなる、敗血症を治療または防止する方法。 請求項8.治療用サイトカインまたは炎症剌激物の毒性を低下させる方法であっ て、サイトカインまたは刺激物の投与の前、最中、または後に治療的に有効量の ピリミジンヌクレオチド前駆体を動物に投与することよりなる、上記方法。 請求項9.ピリミジンヌクレオチド前駆体は、ウリジン、シチジン、オロト酸、 あるいはウリジン、シチジン、またはオロト酸のアシル誘導体、あるいは薬剤と して許容されるその塩である、請求項8に記載の方法。 請求項10.ウリジンのアシル誘導体はトリアセチルウリジンである、請求項9 に記載の方法。 請求項11.サイトカインまたは剌激物は、インターロイキン−1、インターロ イキン−2、インターロイキン−6、腫瘍壊死因子、エンドトキシン、真菌の多 糖類、および2本鎖RNAよりなる群から選択される、請求項8に記載の方法。 請求項12.さらにウリジンホスホリラーゼの阻害剤を投与する工程よりなる、 請求項8に記載の方法。 請求項13.治療用サイトカインまたは炎症刺激物の毒性を低下させる方法であ って、サイトカインまたは刺激物の投与の前、最中、または後に治療的に有効量 のウリジンホスホリラーゼの阻害剤を動物に投与することよりなる、上記方法。 請求項14.サイトカインまたは刺激物は、インターロイキン−1、インターロ イキン−2、インターロイキン−6、腫瘍壊死因子、エンドトキシン、真菌の多 糖類、および2本鎖RNAよりなる群から選択される、請求項13に記載の方法 。 請求項15.治療的に有効量の治療用サイトカインまたは炎症性刺激物、および サイトカインまたは刺激物の投与の前、最中、または後に治療的に有効量のピリ ミジンヌクレオチド前駆体を動物に投与することよりなる、癌を治療する方法。 請求項16.ピリミジンヌクレオチド前駆体は、ウリジン、シチジン、オロト酸 、あるいはウリジン、シチジン、またはオロト酸のアシル誘導体、あるいは薬剤 として許容されるその塩である、請求項15に記載の方法。 請求項17.ウリジンのアシル誘導体はトリアセチルウリジンである、請求項1 6に記載の方法。 請求項18.サイトカインまたは刺激物は、インターロイキン−1、インターロ イキン−2、インターロイキン−6、腫瘍壊死因子、エンドトキシン、真菌の多 糖類、および2本鎖RNAよりなる群から選択される、請求項15に記載の方法 。 請求項19.さらにウリジンホスホリラーゼの阻害剤を投与する工程よりなる、 請求項15に記載の方法。 請求項20.治療的に有効量の治療用サイトカインまたは炎症性剌激物、および サイトカインまたは刺激物の投与の前、最中、または後に治療的に有効量のウリ ジンホスホリラーゼの阻害剤を動物に投与することよりなる、癌を治療する方法 。 請求項21.サイトカインまたは刺激物は、インターロイキン−1、インターロ イキン−2、インターロイキン−6、腫瘍壊死因子、エンドトキシン、真菌の多 糖類、および2本鎖RNAよりなる群から選択される、請求項20に記載の方法 。 請求項22.治療的に有効量のウリジン、シチジンまたはオロト酸のアシル誘導 体、あるいは薬剤として許容されるその塩を動物に投与することよりなる、炎症 性肝炎を治療または防止する方法。 請求項23.ウリジンのアシル誘導体はトリアセチルウリジンである、請求項2 2に記載の方法。 請求項24.さらにウリジンホスホリラーゼの阻害剤を投与する工程を含む、請 求項22に記載の方法。 請求項25.治療的に有効量のウリジンホスホリラーゼの阻害剤を動物に投与す ることよりなる、炎症性肝炎を治療または防止する方法。 請求項26.治療的に有効量のウリジンまたはシチジンを動物に投与することよ りなる、炎症性肝炎を治療または防止する方法。 請求項27.1日当たり2から40グラムのウリジンまたはシチジンを投与する 、請求項26に記載の方法。 請求項28.治療的に有効量のピリミジンヌクレオチド前駆体を動物に静脈内投 与することよりなる、完全静脈栄養を受けている動物の肝臓損傷を治療または防 止する方法。 請求項29.ピリミジンヌクレオチド前駆体は、ウリジン、シチジン、オロト酸 、あるいはウリジン、シチジン、またはオロト酸のアシル誘導体、あるいは薬剤 として許容されるその塩である、請求項28に記載の方法。 請求項30.1日当たり2から40グラムのピリミジンヌクレオチド前駆体を投 与する、請求項28に記載の方法。 請求項31.さらにウリジンホスホリラーゼの阻害剤を投与する工程を含む、請 求項28に記載の方法。 請求項32.ウリジンホスホリラーゼの阻害剤を動物に投与することよりなる、 完全静脈栄養を受けている動物の肝臓損傷を治療または防止する方法。 請求項33.治療的に有効量のピリミジンヌクレオチド前駆体を動物に投与する ことよりなる、肝臓移植を受けている動物の肝臓損傷を治療または防止する方法 。 請求項34.ピリミジンヌクレオチド前駆体は、ウリジン、シチジン、オロト酸 、あるいはウリジン、シチジン、またはオロト酸のアシル誘導体、あるいは薬剤 として許容されるその塩である、請求項33に記載の方法。 請求項35.1日当たり2から40グラムのピリミジンヌクレオチド前駆体を投 与する、請求項33に記載の方法。 請求項36.さらにウリジンホスホリラーゼの阻害剤を投与する工程を含む、請 求項33に記載の方法。 請求項37.ウリジンホスホリラーゼの阻害剤を動物に投与することよりなる、 肝臓移植を受けている動物の肝臓損傷を治療または防止する方法。 請求項38.a)ピリミジンヌクレオチド前駆体のアシル誘導体、およびb)ウ リジンホスホリラーゼの阻害剤よりなる組成物。 請求項39.a)ピリミジンヌクレオチド前駆体のアシル誘導体、およびb)プ リンヌクレオチド前駆体よりなる組成物。 請求項40.ピリミジンヌクレオチド前駆体は、ウリジン、シチジン、またはオ ロト酸塩である、請求項39に記載の組成物。 請求項41.プリンヌクレオチド前駆体は、イノシン、アデノシン、あるいはイ ノシンまたはアデノシンのアシル誘導体である、請求項39に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98773092A | 1992-12-08 | 1992-12-08 | |
US987,730 | 1992-12-08 | ||
PCT/US1993/011531 WO1994013687A1 (en) | 1992-12-08 | 1993-12-01 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004348587A Division JP2005162757A (ja) | 1992-12-08 | 2004-12-01 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
JP2007177101A Division JP2007332144A (ja) | 1992-12-08 | 2007-07-05 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08503699A true JPH08503699A (ja) | 1996-04-23 |
Family
ID=25533509
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6510442A Withdrawn JPH08503699A (ja) | 1992-12-08 | 1993-12-01 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
JP2004348587A Withdrawn JP2005162757A (ja) | 1992-12-08 | 2004-12-01 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
JP2007177101A Pending JP2007332144A (ja) | 1992-12-08 | 2007-07-05 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004348587A Withdrawn JP2005162757A (ja) | 1992-12-08 | 2004-12-01 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
JP2007177101A Pending JP2007332144A (ja) | 1992-12-08 | 2007-07-05 | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP0679160B1 (ja) |
JP (3) | JPH08503699A (ja) |
KR (1) | KR100315890B1 (ja) |
CN (2) | CN1089239C (ja) |
AT (1) | ATE282627T1 (ja) |
AU (2) | AU5730594A (ja) |
CA (2) | CA2588495C (ja) |
DE (1) | DE69333699T2 (ja) |
ES (1) | ES2229212T3 (ja) |
HK (1) | HK1004484A1 (ja) |
IL (1) | IL107900A (ja) |
MX (1) | MX9307765A (ja) |
PT (1) | PT679160E (ja) |
WO (1) | WO1994013687A1 (ja) |
ZA (1) | ZA939208B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100409A1 (fr) * | 2001-06-11 | 2002-12-19 | Kyowa Hakko Kogyo Co., Ltd. | Compositions anti-inflammatoires et antitussives |
JP2002544165A (ja) * | 1999-05-05 | 2002-12-24 | ウプグンドゥリ,スリニヴァス | 急性及び慢性炎症の新規な特異的抑制剤 |
WO2023058731A1 (ja) | 2021-10-07 | 2023-04-13 | ヤマサ醤油株式会社 | 皮膚外用組成物及びその利用、並びに皮膚外用組成物原料 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329350B1 (en) | 1987-10-28 | 2001-12-11 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
US5691320A (en) | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
CN101066276A (zh) | 1994-07-01 | 2007-11-07 | 威尔斯塔特医疗公司 | 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体 |
SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
US20020006913A1 (en) | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
US20180325933A1 (en) * | 2014-07-16 | 2018-11-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling |
EP3002010A1 (en) * | 2014-09-30 | 2016-04-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling |
WO2018038599A1 (en) * | 2016-08-23 | 2018-03-01 | N.V. Nutricia | Product and method for increasing uridine concentration in blood plasma |
CN114469981A (zh) * | 2021-12-16 | 2022-05-13 | 中国科学院动物研究所 | 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53117617A (en) * | 1977-03-24 | 1978-10-14 | Nippon Yakin Kogyo Co Ltd | Highhstrength austenite stainless steel |
JPS53117618A (en) * | 1977-03-24 | 1978-10-14 | Nippon Yakin Kogyo Co Ltd | Highhstrength austenite stainless steel |
JPS5585659A (en) * | 1978-12-25 | 1980-06-27 | Daido Steel Co Ltd | Free-cutting nonmagnetic high-manganese steel |
JPS58126956A (ja) * | 1982-01-22 | 1983-07-28 | Nippon Steel Corp | プレス加工性の優れた高強度薄鋼板 |
JPS58185722A (ja) * | 1982-04-21 | 1983-10-29 | Nippon Steel Corp | オ−ステナイト鋼板および鋼帯の製造方法 |
US4847046A (en) * | 1985-08-31 | 1989-07-11 | Korea Advanced Institute Of Science And Technology | Ultra-low temperature alloy and process for manufacturing the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1297398A (ja) * | 1969-08-06 | 1972-11-22 | ||
US3868451A (en) * | 1971-03-30 | 1975-02-25 | Abbott Lab | Adenosine-5{40 -esters in treating angina pectoris |
WO1985000608A1 (en) * | 1983-07-20 | 1985-02-14 | Teijin Limited | Antineoplastic agent |
JPS60174797A (ja) * | 1984-02-21 | 1985-09-09 | Funai Corp | Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤 |
CA1329932C (en) * | 1987-10-28 | 1994-05-31 | Reid Von Borstel | Acyl deoxyribonucleoside derivatives and uses thereof |
DE3883374T2 (de) * | 1987-10-28 | 1993-12-09 | Pro Neuron Inc | Acylatiertes uridin und cytidin und deren verwendungen. |
US4874602A (en) * | 1988-02-22 | 1989-10-17 | Paul Calabresi | Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine |
US5077280A (en) * | 1988-04-12 | 1991-12-31 | Brown University Research Foundation | Treatment of viral infections |
JP2529605B2 (ja) * | 1989-10-23 | 1996-08-28 | 株式会社大塚製薬工場 | 免疫賦活剤 |
JPH03169815A (ja) * | 1989-11-29 | 1991-07-23 | Nippon Mining Co Ltd | 肝臓障害予防及び治療剤 |
US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
-
1993
- 1993-12-01 EP EP94903322A patent/EP0679160B1/en not_active Expired - Lifetime
- 1993-12-01 JP JP6510442A patent/JPH08503699A/ja not_active Withdrawn
- 1993-12-01 DE DE69333699T patent/DE69333699T2/de not_active Expired - Fee Related
- 1993-12-01 ES ES94903322T patent/ES2229212T3/es not_active Expired - Lifetime
- 1993-12-01 AT AT94903322T patent/ATE282627T1/de not_active IP Right Cessation
- 1993-12-01 EP EP04020415A patent/EP1486210A1/en not_active Withdrawn
- 1993-12-01 CA CA002588495A patent/CA2588495C/en not_active Expired - Fee Related
- 1993-12-01 KR KR1019950702327A patent/KR100315890B1/ko not_active IP Right Cessation
- 1993-12-01 CA CA002150940A patent/CA2150940C/en not_active Expired - Fee Related
- 1993-12-01 PT PT94903322T patent/PT679160E/pt unknown
- 1993-12-01 WO PCT/US1993/011531 patent/WO1994013687A1/en active IP Right Grant
- 1993-12-01 AU AU57305/94A patent/AU5730594A/en not_active Abandoned
- 1993-12-06 IL IL10790093A patent/IL107900A/en not_active IP Right Cessation
- 1993-12-07 CN CN93121700A patent/CN1089239C/zh not_active Expired - Fee Related
- 1993-12-08 ZA ZA939208A patent/ZA939208B/xx unknown
- 1993-12-08 MX MX9307765A patent/MX9307765A/es unknown
-
1998
- 1998-04-29 HK HK98103632A patent/HK1004484A1/xx not_active IP Right Cessation
- 1998-08-05 AU AU78813/98A patent/AU732120B2/en not_active Ceased
-
2000
- 2000-11-29 CN CNB001344811A patent/CN1211089C/zh not_active Expired - Fee Related
-
2004
- 2004-12-01 JP JP2004348587A patent/JP2005162757A/ja not_active Withdrawn
-
2007
- 2007-07-05 JP JP2007177101A patent/JP2007332144A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53117617A (en) * | 1977-03-24 | 1978-10-14 | Nippon Yakin Kogyo Co Ltd | Highhstrength austenite stainless steel |
JPS53117618A (en) * | 1977-03-24 | 1978-10-14 | Nippon Yakin Kogyo Co Ltd | Highhstrength austenite stainless steel |
JPS5585659A (en) * | 1978-12-25 | 1980-06-27 | Daido Steel Co Ltd | Free-cutting nonmagnetic high-manganese steel |
JPS58126956A (ja) * | 1982-01-22 | 1983-07-28 | Nippon Steel Corp | プレス加工性の優れた高強度薄鋼板 |
JPS58185722A (ja) * | 1982-04-21 | 1983-10-29 | Nippon Steel Corp | オ−ステナイト鋼板および鋼帯の製造方法 |
US4847046A (en) * | 1985-08-31 | 1989-07-11 | Korea Advanced Institute Of Science And Technology | Ultra-low temperature alloy and process for manufacturing the same |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002544165A (ja) * | 1999-05-05 | 2002-12-24 | ウプグンドゥリ,スリニヴァス | 急性及び慢性炎症の新規な特異的抑制剤 |
WO2002100409A1 (fr) * | 2001-06-11 | 2002-12-19 | Kyowa Hakko Kogyo Co., Ltd. | Compositions anti-inflammatoires et antitussives |
WO2023058731A1 (ja) | 2021-10-07 | 2023-04-13 | ヤマサ醤油株式会社 | 皮膚外用組成物及びその利用、並びに皮膚外用組成物原料 |
Also Published As
Publication number | Publication date |
---|---|
IL107900A (en) | 1999-12-22 |
CA2150940A1 (en) | 1994-06-23 |
EP0679160B1 (en) | 2004-11-17 |
WO1994013687A1 (en) | 1994-06-23 |
IL107900A0 (en) | 1994-05-30 |
ZA939208B (en) | 1994-08-08 |
JP2007332144A (ja) | 2007-12-27 |
DE69333699D1 (de) | 2004-12-23 |
EP0679160A4 (en) | 1997-06-11 |
AU7881398A (en) | 1998-10-08 |
CN1095268A (zh) | 1994-11-23 |
CN1089239C (zh) | 2002-08-21 |
ES2229212T3 (es) | 2005-04-16 |
PT679160E (pt) | 2005-02-28 |
EP1486210A1 (en) | 2004-12-15 |
CN1309970A (zh) | 2001-08-29 |
KR100315890B1 (ko) | 2002-06-27 |
MX9307765A (es) | 1994-06-30 |
CA2150940C (en) | 2007-08-21 |
CA2588495C (en) | 2009-11-17 |
KR950704342A (ko) | 1995-11-20 |
HK1004484A1 (en) | 1998-11-27 |
DE69333699T2 (de) | 2006-07-27 |
ATE282627T1 (de) | 2004-12-15 |
EP0679160A1 (en) | 1995-11-02 |
CA2588495A1 (en) | 1994-06-23 |
AU5730594A (en) | 1994-07-04 |
AU732120B2 (en) | 2001-04-12 |
JP2005162757A (ja) | 2005-06-23 |
CN1211089C (zh) | 2005-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7173017B1 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
JP2008007525A (ja) | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 | |
JP2007332144A (ja) | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 | |
US6344447B2 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
JP2584947B2 (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療 | |
JP2018535989A (ja) | 癌治療のためのシタラビンコンジュゲート | |
CN1312254A (zh) | 新的核苷 | |
US6329350B1 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
JP2004506684A (ja) | 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法 | |
US20210338704A1 (en) | Cytarabine conjugates for cancer therapy | |
AU2004201154A1 (en) | Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Hepatitis | |
AU2005232281A1 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
AU5262499A (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
AU2006236108A1 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040901 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041201 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060801 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061101 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070625 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080724 Year of fee payment: 10 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070809 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080408 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080416 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080609 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080701 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080703 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090724 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |